Key Laboratory for Biorheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Bioengineering College of Chongqing University, Chongqing, 400030, China.
Chongqing Municipality Clinical Research Center for Endocrinology and Metabolic Diseases, Chongqing University Three Gorges Hospital, Chongqing, 404000, China.
Adv Sci (Weinh). 2023 Feb;10(6):e2205093. doi: 10.1002/advs.202205093. Epub 2023 Jan 26.
Biomimetic cell membrane camouflaged technology has drawn extensive attention as a feasible and efficient way to realize the biological functions of nanoparticles from the parent cells. As the burgeoning nanotherapeutic, the right-side-out orientation self-assembly and pathological dependent "on-demand" cargo release of cell membrane camouflaged nanocarriers remarkably limit further development for practical applications. In the present study, a spontaneously right-side-out-orientated coupling-driven ROS-sensitive nanotherapeutic has been constructed for target endothelial cells (ECs) repair through the synergistic effects of spontaneously right-side-out-orientated camouflaging. This condition results from the specific affinity between the intracellular domain of key transmembrane receptors band 3 on cell membrane inner leaflet and the corresponding P4.2 peptide-modified nanoparticles without the additional coextrusion. The "on-demand" cargo release results from the pathological ROS-cleavable prodrug. Particularly, the red blood cell camouflaged nanotherapeutics (RBC-LVTNPs) can enhance target drug delivery through low oscillatory shear stress (LSS) blood flow in the injured ECs lesion. Both in vitro and in vivo results collectively confirm that RBC-LVTNPs can restore the damaged ECs and function with the recovered vascular permeability and low inflammation microenvironment. The findings provide a powerful and universal approach for developing the biomimetic cell membrane camouflaged nanotechnology.
仿生细胞膜伪装技术作为一种可行且有效的方法,可以从亲本细胞中实现纳米粒子的生物学功能,引起了广泛关注。作为新兴的纳米治疗方法,细胞膜伪装纳米载体的正确向外取向自组装和病理依赖的“按需”货物释放,显著限制了其实际应用的进一步发展。在本研究中,通过自发的正确向外取向偶联驱动的 ROS 敏感纳米治疗,构建了一种用于靶向内皮细胞 (ECs) 修复的纳米治疗,通过自发的正确向外取向伪装的协同作用。这种情况是由于细胞膜内叶上带 3 关键跨膜受体细胞内结构域与相应的 P4.2 肽修饰纳米颗粒之间的特异性亲和力,而无需额外的共挤出。“按需”货物释放是由病理 ROS 可切割前药引起的。特别地,红细胞伪装纳米治疗剂 (RBC-LVTNPs) 可以通过受损 ECs 病变中低振荡剪切应力 (LSS) 血流增强靶向药物输送。体外和体内的结果都共同证实,RBC-LVTNPs 可以恢复受损的 ECs 功能,并恢复血管通透性和低炎症微环境。这些发现为开发仿生细胞膜伪装纳米技术提供了一种强大而通用的方法。